{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:19:30Z","timestamp":1778869170784,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.jaad.2006.11.007","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T07:14:10Z","timestamp":1166858050000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial\u00a0seborrheic dermatitis"],"prefix":"10.1016","volume":"57","author":[{"given":"Erin M.","family":"Warshaw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross Jon","family":"Wohlhuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel A.","family":"Wenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacharitha","family":"Bowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Irving","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogera L.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Parneix-Spake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.11.007_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2230.1997.d01-231.x","article-title":"Dandruff and seborrheic dermatitis: causes and management","volume":"22","author":"Hay","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128071-200405060-00006","article-title":"Role of antifungal agents in the treatment of seborrheic dermatitis","volume":"5","author":"Gupta","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib3","first-page":"771","article-title":"Role of Malassezia yeast (pityrosporum) in seborrheic dermatitis (sd)","volume":"15","author":"Mirza","year":"2005","journal-title":"J Coll Physicians Surg Pak"},{"key":"10.1016\/j.jaad.2006.11.007_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1365-2133.1998.02362.x","article-title":"Seborrheic dermatitis is not caused by an altered immune response to Malassezia yeast","volume":"139","author":"Parry","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2133.1990.tb08241.x","article-title":"The permissive effect of sebum in seborrheic dermatitis: an explanation of the rash in neurological disorders","volume":"122","author":"Cowley","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2133.2003.04934.x","article-title":"Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis","volume":"148","author":"Furue","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0738-081X(97)00020-5","article-title":"Corticosteroids","volume":"15","author":"Hugues","year":"1997","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s004030050343","article-title":"Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner","volume":"290","author":"Hultsch","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2006.11.007_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mai.2001.116865","article-title":"The ascomycin macrolactam pimecrolimus (pimecrolimus, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils","volume":"108","author":"Zuberbier","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2006.11.007_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mpd.2003.65","article-title":"Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants","volume":"142","author":"Ho","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2006.11.007_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000078462","article-title":"Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis","volume":"208","author":"Meurer","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.11.007_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children","volume":"110","author":"Wahn","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaad.2006.11.007_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2133.2001.04076.x","article-title":"The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study","volume":"144","author":"Queille-Roussel","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib15","unstructured":"Pediatric Advisory Committee. Available at: URL:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4089b2.htm. Accessed October 12, 2006."},{"key":"10.1016\/j.jaad.2006.11.007_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2133.2004.06208.x","article-title":"Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: a randomized open-label clinical trial","volume":"151","author":"Rigopoulos","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jaad.2006.01.011","article-title":"Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation","volume":"54","author":"High","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib18","first-page":"191","article-title":"Pimecrolimus cream 1% an be an effective treatment for seborrheic dermatitis of the face and trunk","volume":"30","author":"Rallis","year":"2004","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.jaad.2006.11.007_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archderm.142.8.1066","article-title":"Pimecrolimus cream 1% vs hydrocortone acetate cream 1% in the treatment of facial seborrheic dermatitis: a randomized investigator-blind, clincial trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib20","first-page":"207","article-title":"Pimecrolimus: a new treatment for seborrheic dermatitis","volume":"70","author":"Crutchfield","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.11.007_bib21","first-page":"13","article-title":"Topical pimecrolimus in the treatment of seborrheic dermatitis","volume":"9","author":"Brownell","year":"2003","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2006.11.007_bib22","unstructured":"Kapteine L, Karls R, Zigure S. Pimecrolimus cream 1% in the treatment of seborrheic dermatitis. Eur Acad Dermatol Venereol. Poster presentation. Available at: http:\/\/www.eadv2005.com\/abstract\/posters\/P01.doc. Accessed November 28, 2006."},{"key":"10.1016\/j.jaad.2006.11.007_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00015550510040040","article-title":"Pimecrolimus cream 1% is effective in seborrheic dermatitis refractory to treatment with topical corticosteroids","volume":"86","author":"Cunha","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.11.007_bib24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/archderm.138.11.1437","article-title":"Differential effects of photoaging vs intrinsic aging on the vascularization of human skin","volume":"138","author":"Chung","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2133.2001.04194.x","article-title":"Randomized, placebo-controlled, double-blind study on the clinical efficacy of ciclopiroxolamine 1% cream in facial seborrheic dermatitis","volume":"144","author":"Dupuy","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2004.06.010","article-title":"Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study","volume":"51","author":"Gribetz","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archderm.141.9.1168","article-title":"Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream","volume":"141","author":"Gorman","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.11.007_bib28","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/archderm.140.8.1014","article-title":"Alcohol-induced, application site-erythema after topical immunomodulator use and its inhibition by aspirin: report of a double-blind, controlled pilot trial","volume":"140","author":"Ehst","year":"2004","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:22Z","timestamp":1759269982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206040229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0190962206040229"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.11.007","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial\u00a0seborrheic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}